A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma
Clinical trial NCT06261359 · RECRUITING
Trial details
- NCT number
- NCT06261359
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-19
- Primary completion
- 2025-04-01
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.